Clinical use of plerixafor in combination with granulocyte-colony stimulating factor in hematopoietic stem cell transplantation
Cedar J Fowler1, Richard T Maziarz21Laboratory of Clinical Infectious Diseases – NIAID, National Institutes of Health, Bethesda, MD, USA; 2Adult Blood and Marrow Stem Cell Transplant Program, Oregon Health and Science University, Portland, OR, USAAbstract: Plerixafor is a CXC4:CXCL12 a...
Main Authors: | Cedar J Fowler, Richard T Maziarz |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-05-01
|
Series: | Transplant Research and Risk Management |
Online Access: | http://www.dovepress.com/clinical-use-of-plerixafor-in-combination-with-granulocyte-colony-stim-a4418 |
Similar Items
-
Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin’s lymphoma and multiple myeloma
by: Louis M Pelus, et al.
Published: (2011-02-01) -
Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
by: Dwight D. Eplin, et al.
Published: (2019-10-01) -
Use of plerixafor for hematopoietic stem cells mobilization in allograft donors
by: D. N. Balashov, et al.
Published: (2015-01-01) -
Use of plerixafor for hematopoietic stem cells mobilization in allograft donors
by: D. N. Balashov, et al.
Published: (2015-01-01) -
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
by: Michael M. B. Green, et al.
Published: (2016-08-01)